Biohit Oyj’s Financial Reporting and Annual General Meeting in 2026
Biohit Oyj, Stock Exchange Release November 26th, 2025, at 2:00 pm (EET)
Biohit Oyj’s planned release schedule for financial reports in 2026 is as follows:
- Financial Statement Release for 2025 on Wednesday February 11th, 2026, at 9:30 am.
- The Annual Report, including Financial Statement and Report of the Board of Directors for 2025 on Wednesday March 18th, 2026, at 9:30 am.
- Half-year financial report for January-June 2026 on Wednesday August 5th, 2026, at 9:30 am.
Biohit observes a silent period of 30 days before results are published. During this period, Biohit’s management and other personnel will not provide information about the company’s financial position or market related comments, nor will they meet with representatives from equity markets or the financial media.
The published financial reports and other stock exchange releases are available on Biohit's website at: https://investors.biohithealthcare.com/en/.
The website also contains an online form for ordering electronic copies, which will be e-mailed to you, available at: https://investors.biohithealthcare.com/en/releases/subscribe.
Biohit Oyj’s Annual General Meeting has been planned for Wednesday June 3rd, 2026, at 2:00 pm. The Board of Directors will call the General meeting later.
Additional information:
Jussi Hahtela, CEO, Biohit Oyj
tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.